Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;10(4):278-81.
doi: 10.1016/j.jcf.2011.02.001. Epub 2011 Mar 8.

Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening

Mei W Baker  1 , Molly Groose, Gary Hoffman, Michael Rock, Hara Levy, Philip M Farrell
Affiliations

Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening

Mei W Baker et al. J Cyst Fibros. 2011 Jul.

Abstract

Background: There has been great variation and uncertainty about how many and what CFTR mutations to include in cystic fibrosis (CF) newborn screening algorithms, and very little research on this topic using large populations of newborns.

Methods: We reviewed Wisconsin screening results for 1994-2008 to identify an ideal panel.

Results: Upon analyzing approximately 1 million screening results, we found it optimal to use a 23 CFTR mutation panel as a second tier when an immunoreactive trypsinogen (IRT)/DNA algorithm was applied for CF screening. This panel in association with a 96th percentile IRT cutoff gave a sensitivity of 97.3%, but restricting the DNA tier to F508del was associated with 90% (P<.0001).

Conclusions: Although CFTR panel selection has been challenging, our data show that a 23 mutation method optimizes sensitivity and is advantageous. The IRT cutoff value, however, is actually more critical than DNA in determining CF newborn screening sensitivity.

PubMed Disclaimer

References

    1. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;1:472–474. - PubMed
    1. Travert G, Duhamel JF. Systematic neonatal screening for mucoviscidosis using an immunoreactive trypsin blood assay. Evaluation of 80,000 tests. Arch Fr Pediatr. 1983:295–8. - PubMed
    1. Hammond KB, Abman SH, Sokol RJ, Accurso FJ. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med. 1991;325:769–74. - PubMed
    1. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH, Wei LJ. Newborn screening for cystic fibrosis is complicated by the age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990;81:1001–1007. - PubMed
    1. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. The application of DNA analysis in a population screening program for neonatal diagnosis of cystic fibrosis: comparison of screening protocols. Am J Hum Genet. 1993;52:616–626. - PMC - PubMed

Publication types